Plus Therapeutics (PSTV) appointed Michael Rosol as Chief Development Officer. Rosol will lead the company’s clinical, pre-clinical, and biomarker development activities. Rosol most recently served as Chief Medical Officer and Senior Vice President at Navidea Biopharmaceuticals. Prior to his most recent role, Rosol worked at Novartis Pharmaceuticals.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV: